Thomas Cluzeau (T Cluzeau)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 31

Top Topics

Acute Myeloid Leukemia

Peritoneal Dialysis

Stem Cell Transplantation

Top Venues

Bone marrow transplantation

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stéphane M Schneider, Thomas Cluzeau
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial. Bone marrow transplantation 59 (7) (2024)
David Rombaut, Carine Lefèvre, Tony Rached, Sabrina Bondu, Anne Letessier, Raphaël M Mangione, Batoul Farhat, Auriane Lesieur-Pasquier, Daisy Castillo-Guzman, Ismael Boussaid, Chloé Friedrich, Aurore Tourville, Magali De Carvalho, Francoise Levavasseur, Marjorie Leduc, Morgane Le-Gall, Sarah Battault, Marie Temple, Alexandre Houy, Didier Bouscary, Lise Willems, Sophie Park, Sophie Raynaud, Thomas Cluzeau, Emmanuelle Clappier, Pierre Fenaux, Lionel Ades, Raphaël Margueron, Michel Wassef, Samar Alsafadi, Nicolas Chapuis, Olivier Kosmider, Eric Solary, Angelos Constantinou, Marc-Henri Stern, Nathalie M Droin, Benoit Palancade, Benoit Miotto, Frédéric Chedin, Michaela Fontenay
Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation. Nature communications 15 (1) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stéphane M Schneider, Thomas Cluzeau
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial. Bone marrow transplantation 59 (7) (2024)
Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stéphane M Schneider, Thomas Cluzeau
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial. Bone marrow transplantation 59 (7) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
David Rombaut, Carine Lefèvre, Tony Rached, Sabrina Bondu, Anne Letessier, Raphaël M Mangione, Batoul Farhat, Auriane Lesieur-Pasquier, Daisy Castillo-Guzman, Ismael Boussaid, Chloé Friedrich, Aurore Tourville, Magali De Carvalho, Francoise Levavasseur, Marjorie Leduc, Morgane Le-Gall, Sarah Battault, Marie Temple, Alexandre Houy, Didier Bouscary, Lise Willems, Sophie Park, Sophie Raynaud, Thomas Cluzeau, Emmanuelle Clappier, Pierre Fenaux, Lionel Ades, Raphaël Margueron, Michel Wassef, Samar Alsafadi, Nicolas Chapuis, Olivier Kosmider, Eric Solary, Angelos Constantinou, Marc-Henri Stern, Nathalie M Droin, Benoit Palancade, Benoit Miotto, Frédéric Chedin, Michaela Fontenay
Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation. Nature communications 15 (1) (2024)
Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stéphane M Schneider, Thomas Cluzeau
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial. Bone marrow transplantation (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
David Rombaut, Carine Lefèvre, Tony Rached, Sabrina Bondu, Anne Letessier, Raphaël M Mangione, Batoul Farhat, Auriane Lesieur-Pasquier, Daisy Castillo-Guzman, Ismael Boussaid, Chloé Friedrich, Aurore Tourville, Magali De Carvalho, Francoise Levavasseur, Marjorie Leduc, Morgane Le-Gall, Sarah Battault, Marie Temple, Alexandre Houy, Didier Bouscary, Lise Willems, Sophie Park, Sophie Raynaud, Thomas Cluzeau, Emmanuelle Clappier, Pierre Fenaux, Lionel Ades, Raphaël Margueron, Michel Wassef, Samar Alsafadi, Nicolas Chapuis, Olivier Kosmider, Eric Solary, Angelos Constantinou, Marc-Henri Stern, Nathalie M Droin, Benoit Palancade, Benoit Miotto, Frédéric Chedin, Michaela Fontenay
Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation. Nature communications 15 (1) (2024)
Pau Montesinos, Francesco Buccisano, Thomas Cluzeau, Lovisa Vennström, Michael Heuser
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2. Cancers 16 (10) (2024)
Pau Montesinos, Francesco Buccisano, Thomas Cluzeau, Lovisa Vennström, Michael Heuser
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2. Cancers 16 (10) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia (2024)
Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stéphane M Schneider, Thomas Cluzeau
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial. Bone marrow transplantation 59 (7) (2024)
Anne-Sophie Kubasch, P Peterlin, Thomas Cluzeau, K S Götze, K Sockel, R Teipel, Madlen Jentzsch, H Attalah, M Sebert, F Chermat, S Gloaguen, M Puttrich, Michael Cross, Marie Schneider, S Kayser, D Schipp, A Giagounidis, I Tirado-Gonzalez, A Descot, Arjan A van de Loosdrecht, A Weigert, Klaus H Metzeler, P Fenaux, H Medyouf, Uwe Platzbecker, Lionel Ades
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial. Leukemia (2023)
Alexandre Olivier Gérard, Diane Merino, Alexis Charbinat, Joseph Fournier, Alexandre Destere, Michael Loschi, Thomas Cluzeau, Antoine Sicard, Milou-Daniel Drici
CAR-T Cells and the Kidney: Insights from the WHO Safety Database. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Michael Loschi, Christian Roux, Isabelle Sudaka, Corinne Ferrero-Vacher, Alice Marceau-Renaut, Nicolas Duployez, Thierry Passeron, Thomas Cluzeau
Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Bone marrow transplantation 57 (2) (2022)
Florent Malard, Thomas Cluzeau, Charlotte Jubert, Sarah Lawson, Robert J Ryan, Raj Hanvesakul, Katia Perruccio
Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study. Bone marrow transplantation 57 (4) (2022)
Paul Chauvet, Annalisa Paviglianiti, Myriam Labopin, Hélène Labussière, Nicolas Boissel, Marie Robin, Natacha Maillard, Marie Ouachée-Chardin, Edouard Forcade, Xavier Poire, Sylvain Chantepie, Anne Huynh, Claude Eric Bulabois, Mathieu Leclerc, Sébastien Maury, Patrice Chevallier, Thomas Cluzeau, Jean-Baptiste Mear, Jérôme Cornillon, Karin Bilger, Célestine Simand, Yves Beguin, Marie-Thérèse Rubio, Ibrahim Yakoub-Agha, Eolia Brissot
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC. Bone marrow transplantation (2022)
Michael Loschi, Pierre Fenaux, Thomas Cluzeau
How I Treat TP53 -Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cancers 14 (18) (2022)
David M Swoboda, Rashmi Kanagal-Shamana, Andrew M Brunner, Thomas Cluzeau, Onyee Chan, Najla Al Ali, Guillermo Montalban-Bravo, Quinto J Gesiotto, Alexander Gavralidis, Anthony M Hunter, Jung-Hoon Lee, Andrew T Kuykendall, Chetasi Talati, Kendra L Sweet, Jeffrey E Lancet, Eric Padron, Mohammad Hussaini, Jinming Song, Guillermo Garcia Manero, Rami S Komrokji, David A Sallman
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia 36 (4) (2022)
Thomas Cluzeau, Roberto M Lemoli, James McCloskey, Todd Cooper
Measurable Residual Disease in High-Risk Acute Myeloid Leukemia. Cancers 14 (5) (2022)
Anne Calleja, Michael Loschi, Laurent Bailly, Adeline Morisot, Alice Marceau, Lionel Mannone, Guillaume Robert, Patrick Auberger, Claude Preudhomme, Sophie Raynaud, Fabien Subtil, Pierre Sujobert, Thomas Cluzeau
Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia. Cancer medicine (2022)
Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, Sarah Bertoli, Marie-Anne Hospital, Mael Heiblig, Yohann Desbrosses, Caroline Bonmati, Cécile Pautas, Juliette Lambert, Corentin Orvain, Anne Banos, Florence Pasquier, Pierre Peterlin, Tony Marchand, Madalina Uzunov, Jamilé Frayfer, Pascal Turlure, Thomas Cluzeau, Eric Jourdan, Chantal Himberlin, Emmanuelle Tavernier, Alban Villate, Stephanie Haiat, Marie-Lorraine Chretien, Martin Carre, Sylvain Chantepie, Ioana Vaida, Mathieu Wemeau, Safia Chebrek, Gaelle Guillerm, Romain Guièze, Houria Debarri, Eve Gehlkopf, Kamel Laribi, Ambroise Marçais, Alberto Santagostino, Marie Christine Bene, Ariane Mineur, Arnaud Pigneux, Hervé Dombret, Christian Recher
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Leukemia (2022)
Thomas Cluzeau, Marie Sebert, Ramy Rahmé, Stefania Cuzzubbo, Jacqueline Lehmann-Che, Isabelle Madelaine, Pierre Peterlin, Blandine Bève, Habiba Attalah, Fatiha Chermat, Elsa Miekoutima, Odile Beyne Rauzy, Christian Recher, Aspasia Stamatoullas, Lise Willems, Emmanuel Raffoux, Céline Berthon, Bruno Quesnel, Michael Loschi, Antoine F Carpentier, David A Sallman, Rami S Komrokji, Anouk Walter-Petrich, Sylvie Chevret, Lionel Ades, Pierre Fenaux
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (14) (2021)
David A Sallman, Amy E DeZern, Guillermo Garcia Manero, David P Steensma, Gail J Roboz, Mikkael A Sekeres, Thomas Cluzeau, Kendra L Sweet, Amy F McLemore, Kathy L McGraw, John Puskas, Ling Zhang, Jiqiang Yao, Qianxing Mo, Lisa Nardelli, Najla H Al Ali, Eric Padron, Greg Korbel, Eyal C Attar, Hagop M Kantarjian, Jeffrey E Lancet, Pierre Fenaux, Alan F List, Rami S Komrokji
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (14) (2021)
Thomas Cluzeau, Michael Loschi, Pierre Fenaux, Rami Komrokji, David A Sallman
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. International journal of molecular sciences 22 (18) (2021)
Matthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, Meyling H Cheok, Elise Fournier, Estelle Guerin, Laurène Fenwarth, Bouchra Badaoui, Nicolas Freynet, Emmanuel Benayoun, Daniel Lusina, Isabel Garcia, Claude Gardin, Pierre Fenaux, Cécile Pautas, Bruno Quesnel, Pascal Turlure, Christine Terré, Xavier Thomas, Juliette Lambert, Aline Renneville, Claude Preudhomme, Hervé Dombret, Raphaël A Itzykson, Thomas Cluzeau
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. Leukemia (2021)
Pierre Peterlin, Thomas Cluzeau, Maxime Jullien, Anne-Marie Ngo Nloga, Anne Calleja, Eurydice Angeli, Patrice Chevallier, Thierry Guillaume, Alice Garnier, Amandine Le Bourgeois, Steven Le Gouill, Pierre Fenaux, Lionel Adès, Cécile Bally
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients. British journal of haematology 190 (3) (2020)
Mohamed-Amine Hamouda, Arnaud Jacquel, Guillaume Robert, Alexandre Puissant, Valentine Richez, Romeo Cassel, Nina Fenouille, Sandrine Roulland, Jerome Gilleron, Emmanuel Griessinger, Alix Dubois, Beatrice Bailly-Maitre, Diogo Goncalves, Aude Mallavialle, Pascal Colosetti, Sandrine Marchetti, Martine Amiot, Patricia Gomez-Bougie, Nathalie Rochet, Marcel Deckert, Herve Avet-Loiseau, Paul Hofman, Jean-Michel Karsenti, Pierre-Yves Jeandel, Claudine Blin-Wakkach, Bertrand Nadel, Thomas Cluzeau, Kenneth C Anderson, Jean-Gabriel Fuzibet, Patrick Auberger, Frédéric Luciano
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. The Journal of experimental medicine 213 (9) (2016)